GILEAD SCIENCES, INC. (GILD) Factsheet
GILEAD SCIENCES, INC. (GILD) Stock Analysis
Analysis from 10-Q filed 2025-11-07. Data as of Q4 2025.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 19.1%. FCF margin 32.1%. D/E 1.1x. Source: 10-Q filed 2025-11-07.
| Metric | Value | Context |
|---|---|---|
| ROIC | 19.1% | Solid returns |
| FCF Margin | 32.1% | Strong cash generation |
| Debt/Equity | 1.1x | Moderate leverage |
ROIC 19.1% — Top 25% of sector peers. FCF margin 32.1% — Top 5%.
Explore GILEAD SCIENCES, INC.: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for GILD: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: GILEAD SCIENCES, INC. earns 19.1% ROIC, Top 25% in Healthcare
ROIC TTM 19.1%, sector median -2.6%, Top 25%. DuPont: NOPAT margin 29.6% × asset turnover 0.5x. Gross margin 78.8%. Operating margin 34.0%. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 19.1% | Good | Above sector median of -2.6% |
| Return on Equity (ROE) | 41.8% | Excellent | Efficient use of shareholder equity |
| Gross Margin | 78.8% | Excellent | Strong pricing power |
| Operating Margin | 34.0% | Excellent | Efficient operations |
Cash Flow: GILEAD SCIENCES, INC. generates $9.5B FCF at 32.1% margin, positive NaN/8 quarters
FCF TTM $9.5B. FCF margin 32.1%, Top 5%. OCF/Net income 1.2x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 32.1% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $9.5B | Good | Positive cash generation |
| OCF/Net Income | 1.2x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: GILEAD SCIENCES, INC. at 1.1x leverage
Debt/Equity 1.1x. Total debt $24.9B, cash & investments $7.6B. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Debt to Equity | 1.1x | Adequate | Moderate leverage |
| Net Cash Position | $-17.3B | Warning | Net debt position |
Valuation: GILEAD SCIENCES, INC. trades at 17.9x earnings
P/E 17.9x. EV/Sales 5.8x. FCF yield 6.2%. Dividend yield 2.6%. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| P/E Ratio | 17.9x | Adequate | Reasonable valuation |
| EV/Sales | 5.8x | Adequate | Growth premium priced in |
| FCF Yield | 6.2% | Good | Attractive cash return |
| Dividend Yield | 2.6% | Adequate | Growth focus over income |
Capital Allocation: GILEAD SCIENCES, INC. returns 3.9% shareholder yield
Total shareholder yield 3.9% (div 2.6% + buyback 1.3%). Capital returned $5.9B TTM. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.9% | Good | Dividend + buyback yield combined |
| Buyback Yield | 1.3% | Adequate | Minimal buyback activity |
| Total Capital Returned (TTM) | $5.9B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 19.1% | Top 25% | - |
| Free Cash Flow Margin | 32.1% | Top 5% | - |
| Gross Margin | 78.8% | Top 50% | 1.2x above |
| Operating Margin | 34.0% | Top 25% | 12.7x above |
| Return on Equity (ROE) | 41.8% | Top 25% | - |
| P/E Ratio | 17.9x | N/A | - |
Financial Scorecard
| Metric | GILD | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 19.1% | Good | Top 25% of sector (median: -2.6%) |
| Free Cash Flow Margin | 32.1% | Excellent | Top 5% of sector (median: 0.0%) |
| Gross Margin | 78.8% | Excellent | Top 50% of sector (median: 63.8%) |
| Debt to Equity Ratio | 109.8% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 17.9x | Adequate | Fair value |
| Free Cash Flow Yield | 6.2% | Good | Solid cash yield |
Frequently Asked Questions
Q: What is GILEAD SCIENCES, INC.'s Return on Invested Capital (ROIC)?
GILEAD SCIENCES, INC. (GILD) has a trailing twelve-month Return on Invested Capital (ROIC) of 19.1%. Sector median -2.6%. Source: 10-Q filed 2025-11-07.
Q: What is GILEAD SCIENCES, INC.'s Free Cash Flow Margin?
GILEAD SCIENCES, INC. (GILD) has a free cash flow margin of 32.1%, generating $9.5 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-07.
Q: What is GILEAD SCIENCES, INC.'s P/E ratio and how does it compare to peers?
GILEAD SCIENCES, INC. (GILD) trades at a P/E ratio of 17.9x, which is above the sector median of N/A. EV/Sales 5.8x. FCF yield 6.2%. Source: 10-Q filed 2025-11-07.
Q: Does GILEAD SCIENCES, INC. pay a dividend?
GILEAD SCIENCES, INC. (GILD) currently pays a dividend yield of 2.6%. Total shareholder yield (dividend + buybacks) 3.9%. Source: 10-Q filed 2025-11-07.
Q: How much debt does GILEAD SCIENCES, INC. have?
GILEAD SCIENCES, INC. (GILD) has a debt-to-equity ratio of 1.1x with total debt of $24.9 billion. Net debt $17.3 billion. Source: 10-Q filed 2025-11-07.
Q: What is GILEAD SCIENCES, INC.'s revenue and earnings growth?
GILEAD SCIENCES, INC. (GILD) grew revenue by 2.4% year-over-year. EPS +1676.8% YoY. Source: 10-Q filed 2025-11-07.
Q: Is GILEAD SCIENCES, INC. buying back stock?
GILEAD SCIENCES, INC. (GILD) repurchased $1.9 billion of stock over the trailing twelve months. This represents a buyback yield of 1.3%. Source: 10-Q filed 2025-11-07.
Q: How does GILEAD SCIENCES, INC. compare to competitors in Healthcare?
Compared to other companies in Healthcare, GILEAD SCIENCES, INC. (GILD) shows: ROIC 19.1%, sector median -2.6% (Top 25%). FCF margin 32.1%, sector median 0.0% (Top 5%). Gross margin 78.8%, 15.0pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with GILEAD SCIENCES, INC.?
No quantitative warning flags fired for GILEAD SCIENCES, INC. (GILD) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2025-11-07.
Data Source: Data sourced from 10-Q filed 2025-11-07. TTM metrics as of Q4 2025.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.